HOUSTON, Aug. 7, 2023 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it is investigating potential naked short selling of its stock and has retained well-known analytics…Read More
Moleculin Retains Shareholder Intelligence Services LLC to Investigate Potential Naked Short Selling
